KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Change in Inventory (2016 - 2025)

Gilead Sciences' Change in Inventory history spans 17 years, with the latest figure at $123.0 million for Q4 2025.

  • For Q4 2025, Change in Inventory fell 45.58% year-over-year to $123.0 million; the TTM value through Dec 2025 reached $1.0 billion, up 143.19%, while the annual FY2025 figure was $1.0 billion, 143.19% up from the prior year.
  • Change in Inventory reached $123.0 million in Q4 2025 per GILD's latest filing, down from $515.0 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $515.0 million in Q3 2025 to a low of -$70.0 million in Q3 2021.
  • Average Change in Inventory over 5 years is $130.2 million, with a median of $90.0 million recorded in 2022.
  • Peak YoY movement for Change in Inventory: crashed 369.23% in 2021, then skyrocketed 2925.0% in 2023.
  • A 5-year view of Change in Inventory shows it stood at -$35.0 million in 2021, then surged by 888.57% to $276.0 million in 2022, then increased by 11.23% to $307.0 million in 2023, then fell by 26.38% to $226.0 million in 2024, then plummeted by 45.58% to $123.0 million in 2025.
  • Per Business Quant, the three most recent readings for GILD's Change in Inventory are $123.0 million (Q4 2025), $515.0 million (Q3 2025), and $175.0 million (Q2 2025).